

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/tcr-20-2791">http://dx.doi.org/10.21037/tcr-20-2791</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	We will share the original patient data including baseline characteristics and short-term outcome measures. In addition, we also include data on serological indices, which are rarely published before.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Design and registration we registered on the Chinese Clinical Trial Registry (ChiCTR1800017781) to publish our study protocol.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the data can be updated and the survival data will be obtained.
7	To whom will you share the data?	Interventional radiologists or hepatobiliary surgeons who are interested in efficacy of TACE.
8	For what type of analysis or purpose?	For analysis to identify the possible predictive roles of the MCP-1 levels in HCC patients treated with TACE.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: xqy1984king@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.